

A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SABR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

“Stablemates Trial”

Patient education video online



Part of the challenge of the Stablemates Trial is to help patients understand what their options are, as well as to explain how the prerandomization process works.

This new video, featuring principal investigators Dr. Robert Timmerman and Dr. Hiran Fernando, clearly explains the Stablemates trial in layman’s terms, with the goal of empowering the patient both in their decision to participate and in their selection of a treatment modality.

Bookmark the video [here](#) on YouTube to show patients or go to the Stablemates home page at www.joltca.org. Sites will each receive a DVD in addition. A Spanish version will be available shortly.

Subsite update

Active:

- CHUM-Notre Dame Hospital
- Lifespan Oncology Clinical Research
- UT Southwestern Medical Center

Completed contracts and IRB approval:

- Anne Arundel Medical Center
- Henry Ford Health System
- Mount Nittany Medical Center
- Ochsner Medical Center
- Ohio State University
- Penrose Cancer Center
- Swedish Cancer Institute
- University of Louisville Physicians
- University of Tennessee

Completed contracts:

- Intermountain Medical Center
- Mayo Clinic Rochester
- Memorial University Medical Center
- University of Colorado

IRB approval:

- University of Kentucky
- Curtis & Elizabeth Memorial Health

Visit the Stablemates website

www.joltca.org

Study Co-Chair & Surgery QA	Hiran Fernando, MD hiran.fernando@bmc.org 617.638.5600
Study Co-Chair & Radiation QA.....	Robert Timmerman, MD robert.timmerman@utsw.edu 214.645.7651
Statistician	Chul Ahn, PhD chul.ahn@utsw.edu 214.648.9418
Regulatory	Rossana Berrios rossana.berrios@utsw.edu 214.648.1890
Research Manager	Jean Wu, RN, MSN, OCN jean.wu@utsw.edu 214.648.1892
Contracts / Project Manager.....	Lynn Baker, MBA lynn.baker@utsw.edu 214.648.8038
Newsletter	Dee Hill dee.hill@utsw.edu 214.645.7650

Save the Date: July 14-17

A meeting of Stablemates trial investigators is being planned to coincide with NRG Oncology semiannual meeting in Dallas in July. More details will be announced soon, in the meantime please make plans to attend!

Frequently asked questions

Question: How fast is the rapid review process for radiation therapy plans?

Answer: The purpose of the rapid review is to make sure subsite RT plans meet the constraints of the protocol prior to submission. The initial plan can serve as a reference for future planning.

Once the plan is submitted, a review takes place within 24 hours. How long it takes for the plan to be approved depends on how quickly the submitting institution takes to modify the plan to meet quality constraints.

Wide variations currently exist in RT techniques across the field of radiation oncology. Deviations from the established standards of care in this trial can lead to disparities in the delivered quality of care. These deviations in RT quality can have a direct impact on patient outcomes, potentially confusing the study results. For this reason, we have implemented the rapid review process to ensure standardization in all patient treatments.

New project manager appointed

Lynn Baker, M.B.A., of UT Southwestern has accepted the position of Project Manager with responsibility for the Stablemates trial. She formerly served as a senior IRB coordinator for the university.



A native of Texas, Lynn attended Lewis-Clark State College and earned her M.B.A. at Seattle University.

For any questions regarding contracts, invoicing, patient materials and more, please contact Lynn at lynn.baker@utsw.edu.

Spotlight on: CHUM (Centre Hospitalier de l'Université de Montréal)

The Stablemates trial at CHUM is led by principal investigator Moishe Liberman, M.D., Ph.D.



Dr. Liberman is Professor of Surgery at the University of Montreal and holds the Marcel and Rolande Gosselin Chair in Thoracic Surgical Oncology. He is also director of the CHUM Endoscopic Tracheo-Bronchial and Oesophageal Center.

An eminent researcher and physician, Dr. Liberman became one of North America's youngest professionals to hold a medical chair when he was recruited to CHUM in 2009 at age 34.

CHUM is one of three sites now actively enrolling patients!